Exploring the role of FDG-PET in the assessment of bone marrow involvement in lymphoma patients as interpreted by qualitative and semiquantitative disease metabolic activity parameter

Indian Journal of Cancer

Volumn 47, Issue 4, 2010, Pages 380-384

  Kand, P G ^a   Tiwari, B P ^a   Basu, S ^a   Asopa, R V ^a   Nayak, U N ^a  

^a TATA MEMORIAL HOSPITAL   (India)

Author keywords

Bone marrow biopsy; FDG PET; Hodgkin's disease; Lymphoma; non Hodgkin's lymphoma

Indexed keywords

FLUORODEOXYGLUCOSE; FLUORODEOXYGLUCOSE F 18;

ADULT; BONE MARROW BIOPSY; BONE MARROW CANCER; CLINICAL ARTICLE; CONFERENCE PAPER; DISEASE ACTIVITY; FEMALE; HODGKIN DISEASE; HOSPITALIZATION; HUMAN; INTERMETHOD COMPARISON; MALE; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; QUALITATIVE ANALYSIS; WHOLE BODY PET;

ADULT; BONE MARROW NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHOMA; MALE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 78650083065     PISSN: 0019509X     EISSN: 19984774     Source Type: Journal    
DOI: 10.4103/0019-509X.73569     Document Type: Conference Paper

References (20)

1. Collins CD. PET in lymphoma. Cancer Imaging 2006;6:63-70.
2. Horvth E, Mezei T, Pvai Z, Turcu M, Demian S, Tth E, et al. Diagnostic and differential diagnostic criteria of lymphoid neoplasms in bone marrow trephine biopsies: a study of 87 cases. Rom J Morphol Embryol 2009;50:399-406.
3. Moog F, Bangerter M, Kotzerke J, Guhlmann A, Frickhofen N, Reske SN. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol 1998;16:603-9.
4. Kumar S, Rau AR, Naik R, Kini H, Mathai AM, Pai MR, et al. Bone marrow biopsy in non-Hodgkin lymphoma: A morphological study. Indian J Pathol Microbiol 2009;52:332-8.
5. Pelosi E, Penna D, Deandreis D, Chiappella A, Skanjeti A, Vitolo U, et al. FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on the clinical management. Q J Nucl Med Mol Imaging 2008;52:9-16.
6. Carr R, Barrington SF, Madan B, O'Doherty MJ, Saunders CA, van der Walt J, et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood 1998;91:3340-6.
7. Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, et al. Use of positron emission tomography for response assessment of lymphoma: Consensus of the imaging subcommittee of international harmonization project in lymphoma. J Clin Oncol 2007;25:571-8.
8. Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, et al. Early interim 2-[18 F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage hodgkin's lymphoma: A report from a joint Italian-Danish study. J Clin Oncol 2007;25:3746-52.
9. Spaepen K, Stroobants S, Dupont P, Van Steenweghen S, Thomas J, Vandenberghe P, et al. Prognostic Value of Positron Emission Tomography (PET) with fluorine-18 fluorodeoxyglucose ([18 F]FDG) after first-line chemotherapy in non-hodgkin's lymphoma: Is [18 F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 2001;19:414-9.
10. Tatsumi M, Kitayama H, Sugahara H, Tokita N, Nakamura H, Kanakura Y, et al. Whole-body hybrid PET with 18F-FDG in the staging of non-Hodgkin's lymphoma. J Nucl Med 2001;42:601-08.
11. Schder H, Meta J, C Yap, Ariannejad M, Rao J, Phelps ME, et al. Effect of whole-body 18 F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma. J Nucl Med 2001;42:1139-43.
12. Suh C, Kang YK, Roh JL, Kim MR, Kim JS, Huh J, et al. Prognostic value of tumor 18F-FDG uptake in patients with untreated extranodal natural killer/T-cell lymphomas of the head and neck. J Nucl Med 2008;49:1783-9.
13. Jhanwar YS, Straus DJ. The Role of PET in Lymphoma. J Nucl Med 2007;47:1326-34.
14. Jerusalem G, Beguin Y, Najjar F, Hustinx R, Fassotte MF, Rigo P, et al. Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18FFDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL). Ann Oncol 2001;12:825-30.
15. Pakos EE, Fotopoulos AD, Ioannidis JP. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. J Nucl Med 2005;46:958-63.
16. Anagnostou D. Pitfalls in the pattern of bone marrow infiltration in lymphoproliferative disorders. Curr Diagn Path 2005;11:170-9.
17. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised Response Criteria for Malignant Lymphoma. J Clin Oncol 2007;25:579-86.
18. Chetty R, Echezarreta G, Comley M, Gatter K. Immunohistochemistry in apparently normal bone marrow trephine specimens from patients with nodal follicular lymphoma. J Clin Pathol 1995;48:1035-8.
19. Fraga M, Brousset P, Schlaifer D, Payen C, Robert A, Rubie H, et al. Bone marrow involvement in anaplastic large cell lymphoma: immunohistochemical detection of minimal disease and its prognostic significance. Am J Clin Pathol 1995;103:82-9.
20. Elstrom R, Guan L, Baker G, Nakhoda K, Vergilio JA, Zhuang H, et al. Utility of FDG-PET scanning in lymphoma byWHO classification. Blood 2003;101:3875-6.